Keros Therapeutics, Inc. (KROS) Stock Trending Lower Despite Success of Phase 2 Clinical Trial of KER-050
Keros Therapeutics, Inc. (KROS) stock prices were down by 11.98% shortly after market trading commenced on June 23rd, 2021, bringing the price per share down to USD$46.28. Success of Phase 2 Trial June 22nd, 2021 saw the company announce preliminary results rom Cohorts 1 and 2 of its Phase 2 clinical trial. The trial is […]